Beiersdorf's venture capital unit, Oscar & Paul Beiersdorf Venture Capital, focuses on shaping the future of skincare by investing in breakthrough ideas, technologies, and business models across sustainability, life sciences & biotech, digital solutions & digital health, and beauty tech. Their strategy involves collaborating with startups, providing access to Beiersdorf's extensive resources, and actively investing in Series A stage companies, primarily in Europe, North America, Korea, and Israel.
50% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-a (50% of deals). Average disclosed round size is $38.8M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| MMelt&Marble | Series A | $7.3M | Dec 2025 |
| DDeepLife | Series A | $10M | Dec 2024 |
 Evommune, Inc. | Series C | $115M | Oct 2024 |
| DDePoly | Seed | $23M | — |
Top Co-Investors
Last updated: 16 April 2026